Related Experiment Video
Updated: May 12, 2026
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance
A Elenkova1, N Genov, Z Abadzhieva
1Clinical Centre of Endocrinology and Gerontology, Medical University, Sofia. atanaskae@yahoo.com
Background:
Data on the prevalence of macroprolactinemia in patients with prolactinomas is quite limited as the presence of high-molecular prolactin forms is suspected mainly in subjects with mild hyperprolactinemia and negative pituitary imaging.
Objective:
The main objective of this observational case-control study was to assess the prevalence and clinical significance of macroprolactinemia among patients with prolactinomas.
Methods:
The study population consisted of 239 subjects: 131 prolactinoma patients and 108 sex-, age- and ethnicity- matched healthy controls. Macroprolactinemia was defined by a PRL recovery after PEG precipitation of<40%.
Results:
The prevalence of macroprolactinemia among newly diagnosed prolactinoma patients did not differ statistically from the prevalence in the control group (3.5 vs. 3.7%; p=1.000) but was lower although non-significantly than the subgroup of patients treated with dopamine agonists (DA) (3.5 vs.10.8%; p=0.072). Significant association between disruptions of ovarian function and serum levels of the monomeric as well as high-molecular prolactin isoform was found.
Conclusions:
In few cases, the presence of typical hyperprolactinemia-related clinical symptoms and their disappearance after treatment with DA suggests biological activity of macroprolactin comparable with that of monomeric prolactin isoform. Decrease of macroprolactin levels after DA treatment could suggest tumoral origin of the high-molecular isoform in these rare cases. Although macroprolactinemia is considered a benign condition, pituitary imaging, DA treatment, and prolonged follow-up may be necessary in certain cases. An individualized approach to the management of patients with macroprolactinemia should be applied.
Insights
Macroprolactinemia prevalence in prolactinoma patients is similar to controls, but may be linked to ovarian dysfunction. Some cases show biological activity and potential tumoral origin, requiring individualized management.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Oncology
Background:
- Limited data exists on macroprolactinemia prevalence in prolactinoma patients.
- Macroprolactinemia is often suspected in mild hyperprolactinemia with negative pituitary imaging.
Purpose of the Study:
- To determine the prevalence and clinical significance of macroprolactinemia in prolactinoma patients.
- To compare macroprolactinemia prevalence between prolactinoma patients and healthy controls.
Main Methods:
- Observational case-control study with 239 participants (131 prolactinoma patients, 108 controls).
- Macroprolactinemia defined by <40% prolactin (PRL) recovery after PEG precipitation.
Main Results:
- Macroprolactinemia prevalence in newly diagnosed prolactinoma patients (3.5%) did not differ from controls (3.7%).
- Prevalence was lower, though not significantly, in prolactinoma patients compared to those treated with dopamine agonists (DA) (3.5% vs. 10.8%).
- Significant association found between ovarian function disruptions and both monomeric and high-molecular prolactin levels.
Conclusions:
- In rare instances, macroprolactinemia exhibits biological activity similar to monomeric prolactin, potentially originating from the tumor.
- Individualized management, including pituitary imaging, DA treatment, and follow-up, may be necessary for specific macroprolactinemia cases.
Related Concept Videos
01:27Mitral Valve Prolapse I: Introduction
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:19Mitral Valve Prolapse III: Nursing Management
01:25Clinical Significance of Antibiotic Resistance
01:15Hypoglycemia and Glucagon
01:19Cushing Syndrome II: Pathophysiology